Literature DB >> 15193683

Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus.

Hironobu Fukushima1, Seigo Sugiyama, Osamu Honda, Shunichi Koide, Shinichi Nakamura, Tomohiro Sakamoto, Michihiro Yoshimura, Hisao Ogawa, Daisuke Fujioka, Kiyotaka Kugiyama.   

Abstract

OBJECTIVES: This study prospectively examined whether the levels of high remnant-like lipoprotein particles (RLP) cholesterol have a significant risk and influence prognosis in patients with coronary artery disease (CAD) and type II diabetes mellitus (DM).
BACKGROUND: Several studies have shown that triglyceride-rich lipoproteins contribute to atherosclerotic complications in type II DM. However, it remains to be established which triglyceride-rich lipoproteins contribute to this risk.
METHODS: Levels of RLP cholesterol in fasting serum were measured by an immunoseparation method in 240 type II DM patients with (n = 120) or without (n = 120) CAD. The patients with CAD were followed up for a period of < or =24 months until the occurrence of one of the following clinical coronary events: re-admission or coronary revascularization due to recurrent or refractory angina pectoris, nonfatal myocardial infarction, or cardiac death.
RESULTS: Patients with CAD had higher RLP levels than patients without CAD. Multivariate logistic regression analysis showed that high RLP cholesterol levels (>4.7 mg cholesterol/dl, representing the 75th percentile of the distribution of RLP cholesterol levels in control subjects) were a significant risk factor for the presence of CAD, independent of traditional risk factors. Kaplan-Meier analysis demonstrated that higher RLP cholesterol levels in patients with CAD resulted in a significantly higher probability for the development of coronary events. Multivariate Cox hazards analysis showed that high RLP cholesterol levels in patients with CAD were a significant predictor of future coronary events, independent of other risk factors.
CONCLUSIONS: Increased levels of RLP cholesterol are a significant and independent risk factor of CAD and predict future coronary events in patients with CAD and type II DM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193683     DOI: 10.1016/j.jacc.2003.09.074

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

Review 1.  Remnant lipoproteins and atherosclerosis.

Authors:  ThB Twickler; G M Dallinga-Thie; M J Chapman; J S Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

2.  Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.

Authors:  Limin Wang; Rajan Gill; Theresa L Pedersen; Laura J Higgins; John W Newman; John C Rutledge
Journal:  J Lipid Res       Date:  2008-09-23       Impact factor: 5.922

3.  Postprandial lipemia is modified by the presence of the APOB-516C/T polymorphism in a healthy Caucasian population.

Authors:  Pablo Pérez-Martínez; Francisco Pérez-Jiménez; José María Ordovás; Juan Antonio Moreno; Carmen Marín; Rafael Moreno; Yolanda Jiménez-Gómez; Juan Antonio Paniagua; José López-Miranda
Journal:  Lipids       Date:  2007-02-10       Impact factor: 1.880

Review 4.  Triglycerides and remnant particles as risk factors for coronary artery disease.

Authors:  Takamitsu Nakamura; Kiyotaka Kugiyama
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

5.  Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage.

Authors:  Chih-Hao Lee; Kihwa Kang; Isaac R Mehl; Russell Nofsinger; William A Alaynick; Ling-Wa Chong; John M Rosenfeld; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-07       Impact factor: 11.205

6.  Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry.

Authors:  Seth S Martin; Kamil F Faridi; Parag H Joshi; Michael J Blaha; Krishnaji R Kulkarni; Arif A Khokhar; Thomas M Maddox; Edward P Havranek; Peter P Toth; Fengming Tang; John A Spertus; Steven R Jones
Journal:  Clin Cardiol       Date:  2015-10-13       Impact factor: 2.882

7.  A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL₃+IDL]).

Authors:  Heidi T May; John R Nelson; Krishnaji R Kulkarni; Jeffrey L Anderson; Benjamin D Horne; Tami L Bair; Joseph B Muhlestein
Journal:  Lipids Health Dis       Date:  2013-04-26       Impact factor: 3.876

8.  High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke.

Authors:  Jeong-Yeon Kim; Jong-Ho Park; Sang-Wuk Jeong; Dawid Schellingerhout; Jin-Eok Park; Dong Kun Lee; Won Jun Choi; Seok-Lae Chae; Dong-Eog Kim
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

9.  Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.

Authors:  Kentaro Sakamoto; Mitsunobu Kawamura; Takahide Kohro; Masao Omura; Takayuki Watanabe; Keiko Ashidate; Toshiyuki Horiuchi; Hidehiko Hara; Nobuo Sekine; Rina Chin; Motoyoshi Tsujino; Toru Hiyoshi; Motoki Tagami; Akira Tanaka; Yasumichi Mori; Takeshi Inazawa; Tsutomu Hirano; Tsutomu Yamazaki; Teruo Shiba
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

10.  Effects of rs7903146 variation in the Tcf7l2 gene in the lipid metabolism of three different populations.

Authors:  Pablo Perez-Martinez; Ana I Perez-Caballero; Antonio Garcia-Rios; Elena M Yubero-Serrano; Antonio Camargo; Maria J Gomez-Luna; Carmen Marin; Purificacion Gomez-Luna; Aldona Dembinska-Kiec; Fernando Rodriguez-Cantalejo; Francisco J Tinahones; Helen M Roche; Francisco Perez-Jimenez; Jose Lopez-Miranda; Javier Delgado-Lista
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.